Studies related to Serum BDNF and Curcumin

Chronic Supplementation Of Curcumin Enhances The Efficacy Of Antidepressants In Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Effect Increase
Values Plasma (pg/ml). Authors give no baseline or change numbers, only 6 week levels, but claim no statistically significant difference at baseline. Placebo 6 weeks: 310.38 (72.69). Curcumin 6 weeks: 407.28 (94.86)
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 108
Sex Male
Age Range 30-44, 45-64
Body Types Obese, Overweight, Average, Underweight
Notes for this study:
In a randomized, double-blind, placebo-controlled pilot study, 108 male participants with major depression were assigned to take placebo or 1,000 mg of curcuminoids (>95% purity) for 6 weeks. All participants were also given escitalopram.

The curcumin group saw a modestly greater reduction in depression as measured by the Hamilton Depression Rating Scale and the Montgomery–Åsberg Depression Rating Scale, both of which were statistically significant compared with placebo. The percentage of participants achieving at least a 50% reduction in their score was higher in the curcumin group as well.

The curcumin group saw a greater reduction in IL-1β, TNF-α, and salivary cortisol, and an increase in BDNF levels, all of which were statistically significant compared with the placebo group.